Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Ikbel, Achour"'
Autor:
Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel, Patricia LoRusso, Amy Weise, Joseph Eder, Brendan Curti, Michael Oberst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. Methods MEDI0680 wa
Externí odkaz:
https://doaj.org/article/cf9d82e0ebcd4aaeac76ef9a975cf4f7
Autor:
Sneha Berry, Nicolas Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Aleksandra Ogurtsova, Abha Soni, Farah Succaria, Daphne Wang, Charles Roberts, Julie Stein, Elizabeth Engle, Drew Pardoll, Robert Anders, Tricia Cottrell, Janis M. Taube, Ben Tran, Mark Voskoboynik, James Kuo, Yung-Lue Bang, Hyun-Cheo Chung, Myung-Ju Ahn, Sang-We Kim, Ayesh Perera, Daniel Freeman, Ikbel Achour, Raffaella Faggioni, Feng Xiao, Charles Ferte, Charlotte Lemech, Funda Meric-Bernstam, Theresa Werner, Stephen Hodi, Wells Messersmith, Nancy Lewis, Craig Talluto, Mirek Dostalek, Aiyang Tao, Sarah McWhirter, Damian Trujillo, Jason Luke, Chunxiao Xu, BoMarelli, Jin Qi, Guozhong Qin, Huakui Yu, Molly Jenkins, Kin-Ming Lo, Joern-Peter Halle, Yan Lan, Matthew Taylor, Nicholas Vogelzang, Allen Cohn, Daniel Stepan, Robert Shumaker, Corina Dutcus, Matthew Guo, Emmett Schmidt, Drew Rasco, Marcia Brose, Christopher Di Simone, Sharad Jain, Donald Richards, Carlos Encarnacion, James Mier, Jeongshin An, Yeun-yeoul Yang, Won-Hee Lee, Jinho Yang, Jong-kyu Kim, Hyun Goo Kim, Se Hyun Paek, Jun Woo Lee, Joohyun Woo, Jong Bin Kim, Hyungju Kwon, Woosung Lim, Nam Sun Paik, Yoon-Keun Kim, Byung-In Moon, Filip Janku, David Tan, Juan Martin-Liberal, Shunji Takahashi, Ravit Geva, Ayca Gucalp, Xueying Chen, Kulandayan Subramanian, Jennifer Mataraza, Jennifer Wheler, Philippe Bedard
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.
Externí odkaz:
https://doaj.org/article/5e0fdcdf298e4148a8ad792b96d6446a
Autor:
Qike Li, A. Grant Schissler, Vincent Gardeux, Ikbel Achour, Colleen Kenost, Joanne Berghout, Haiquan Li, Hao Helen Zhang, Yves A. Lussier
Publikováno v:
BMC Medical Genomics, Vol 10, Iss S1, Pp 5-16 (2017)
Abstract Background Transcriptome analytic tools are commonly used across patient cohorts to develop drugs and predict clinical outcomes. However, as precision medicine pursues more accurate and individualized treatment decisions, these methods are n
Externí odkaz:
https://doaj.org/article/e41206918a824ae38f85edb7960d8b1f
Autor:
Martin H. Voss, Arun A. Azad, Aaron R. Hansen, Jhanelle E. Gray, Sarah J. Welsh, Xuyang Song, Michael Kuziora, Lina Meinecke, Jorge Blando, Ikbel Achour, Yi Wang, Farzana L. Walcott, Sjoukje F. Oosting
Publikováno v:
Clinical Cancer Research. 28:3032-3041
Purpose: MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase II study evaluated an
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
Supplementary Materials and Methods, and Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238b4ab5c831dd6063dffdf564c8ad3c
https://doi.org/10.1158/2159-8290.22540037
https://doi.org/10.1158/2159-8290.22540037
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca7eaed273b219faf1bb63ec9cf8694
https://doi.org/10.1158/2159-8290.c.6549263
https://doi.org/10.1158/2159-8290.c.6549263
Autor:
Sjoukje F. Oosting, Farzana L. Walcott, Yi Wang, Ikbel Achour, Jorge Blando, Lina Meinecke, Michael Kuziora, Xuyang Song, Sarah J. Welsh, Jhanelle E. Gray, Aaron R. Hansen, Arun A. Azad, Martin H. Voss
Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fba7a4c3002c9cc8f82b28dcf07d21
https://doi.org/10.1158/1078-0432.22487043
https://doi.org/10.1158/1078-0432.22487043
Autor:
Sjoukje F. Oosting, Farzana L. Walcott, Yi Wang, Ikbel Achour, Jorge Blando, Lina Meinecke, Michael Kuziora, Xuyang Song, Sarah J. Welsh, Jhanelle E. Gray, Aaron R. Hansen, Arun A. Azad, Martin H. Voss
Purpose:MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase II study evaluated ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a90975dd8fcf92fc4c41ce20296e40
https://doi.org/10.1158/1078-0432.c.6532443.v1
https://doi.org/10.1158/1078-0432.c.6532443.v1
Autor:
Sjoukje F. Oosting, Farzana L. Walcott, Yi Wang, Ikbel Achour, Jorge Blando, Lina Meinecke, Michael Kuziora, Xuyang Song, Sarah J. Welsh, Jhanelle E. Gray, Aaron R. Hansen, Arun A. Azad, Martin H. Voss
Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05f7f333933fe113b04c91d3acc099d4
https://doi.org/10.1158/1078-0432.22487034.v1
https://doi.org/10.1158/1078-0432.22487034.v1
Autor:
Mohammadhadi Khorrami, Vidya Sankar Viswanathan, Amit Gupta, Qin Li, Ashok Gupta, Ikbel Achour, Brian Fitzgerald, Vamsidhar Velcheti, Anant Madabhushi
Publikováno v:
Regular and Young Investigator Award Abstracts.